A Phase 3 interventional study of Apalutamide and Placebo in Prostate Cancer, sponsored by Aragon Pharmaceuticals, Inc.. Active, not recruiting at 220 sites in 22 countries. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-04.
Sponsored by Aragon Pharmaceuticals, Inc. (part of Johnson & Johnson) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 70 studies testing apalutamide in Prostatic Neoplasms — 14 open to participants now, 36 under way, 12 of them phase 3. apalutamide · Prostatic Neoplasms.
Among the 70 studies testing apalutamide in Prostatic Neoplasms, this one is the 5th largest by enrollment, is one of 3 that started in 2015, is one of 16 in phase 3, reaches primary completion later than 4 of the 35 other live ones, and was the 8th registered.
7,051 studies on the registry are indexed under Prostatic Neoplasms; 1,579 are open to participants now.
Browse Prostatic Neoplasms studies →14 of the 70 studies testing apalutamide in Prostatic Neoplasms are open now, in 11 countries. Recruiting first, the newest first:
Astellas Pharma Global Development, Inc. · Sites in Bulgaria
Ages 50–75 · Men only · Healthy volunteers
Marco Oderda · Sites in Italy
Ages 18–80 · Men only
M.D. Anderson Cancer Center · Sites in United States
Ages 18+ · Men only
Jonsson Comprehensive Cancer Center · Sites in United States
Ages 18+ · Men only
Cambridge University Hospitals NHS Foundation Trust · Sites in United Kingdom
Ages 18+ · Men only
By country, each count listing its studies:
apalutamide: first FDA approval 2018 (ERLEADA), first EMA approval 2019. What it is approved for, and how studies give it, is on its page →
Of the 1,228 Prostatic Neoplasms studies recruiting now, 927 (75%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.
This study: 18 Years and older · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
70 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 13 · Phase 2 39 · Phase 3 16 · Phase 4 2
First in 2010; this study’s year is marked. 3 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,052 is above the median of 60 across 5,349 interventional studies indexed under Prostatic Neoplasms.
Median enrollment 81 across the 70 interventional studies. Of the 29 that completed or were terminated, 16 (55%) have results posted.
This tab as a report to print or save as PDF → With an account.
20 of 70 have an industry lead sponsor. The 10 most frequent:
This study is registered under Aragon Pharmaceuticals, Inc., one of the names counted as Johnson & Johnson. Under that name alone:
Aragon Pharmaceuticals, Inc. is the lead sponsor of 16 studies on the registry; none are open to participants now.
88 studies in Prostatic Neoplasms by Johnson & Johnson: 9 open now, 23 under way, 9 of them phase 3. Of 58 finished, 24 (41%) have results posted.
Among the 88 studies in Prostatic Neoplasms by Johnson & Johnson, this one is the 7th largest by enrollment of the 68 interventional ones that give a count, is one of 6 that started in 2015, is one of 15 in phase 3, reaches primary completion later than 4 of the 22 other live ones, and was the 47th registered.
Johnson & Johnson’s Prostatic Neoplasms studies by the year they started, since 1995.
9 of the studies testing apalutamide in Prostatic Neoplasms that are under way reach primary completion within a year, 4 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03903835Phase 3Karolinska InstitutetProBio: A Biomarker Driven Study in Patients With Metastatic Prostate Cancer | 2026-12 |
| NCT03767244Phase 3Janssen Research & Development, LLCA Study of Apalutamide in Participants With High-Risk, Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy | 2026-12-01 |
| NCT02531516Phase 3Aragon Pharmaceuticals, Inc.An Efficacy and Safety Study of JNJ-56021927 (Apalutamide) in High-risk Prostate Cancer Subjects Receiving Primary Radiation Therapy: ATLAS | 2027-03-01 |
| NCT06274047Phase 3M.D. Anderson Cancer CenterPROSTATE-IQ: Parallel RandOmized STudy of Personalized Apalutamide Treatment and Evaluation to Improve Quality of Life in Post-Operative Radiation With Androgen Axis Suppression. A Phase III Multi-center Study for Men With Detectable PSA After Prostatectomy for Prostate Cancer. | 2027-06-30 |
| NCT06067269Jonsson Comprehensive Cancer CenterHormone Therapy (Apalutamide) and Image-guided Stereotactic Body Radiation Therapy for the Treatment of Patients With Prostate Cancer, HEATWAVE Trial | 2026-12-30 |
Add all 9 to your calendar (.ics) → With an account.
Among the 70 studies testing apalutamide in Prostatic Neoplasms, from their registry updates:
Among Johnson & Johnson’s 88 in Prostatic Neoplasms:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to determine if the addition of apalutamide to ADT provides superior efficacy in improving radiographic progression-free survival (rPFS) or overall survival (OS) for participants with mHSPC.
This is a randomized (study medication assigned to participants by chance), double-blind (neither the researchers nor the participants know what treatment the participant is receiving), placebo-controlled, multinational, multicenter study of apalutamide in participants with mHSPC. The study consists of 4 Phases: Screening Phase (up to 28 days before randomization), Treatment Phase (28 day treatment cycles until disease progression or the occurrence of unacceptable treatment related toxicity), an End of Treatment Phase (until 30 days after the last dose of study drug), and then a Survival Follow up Phase. In the event of a positive study result and notification of unblinding at either of the interim analyses or at the final analysis, participants in the treatment Phase will have the opportunity to enroll in an Open-label Extension Phase, which will allow participants to receive active drug (apalutamide) for approximately 3 years. Participants who are receiving apalutamide in the Open-label Extension Phase may continue receiving apalutamide in the Long-term Extension (LTE) Phase if they will continue to derive benefit from treatment (based on investigator assessment). Participants' safety will be monitored throughout the study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive apalutamide 240 milligram (mg) (4X 60 mg tablets) with ADT.
Drug: Apalutamide · Drug: Androgen Deprivation Therapy (ADT)
Participants will receive matching Placebo with ADT.
Drug: Placebo · Drug: Androgen Deprivation Therapy (ADT)
Participants will receive apalutamide 240 mg (4 x 60 mg) tablets orally once daily in each 28 day treatment cycles.
Also known as: JNJ-56021927, ARN-509
Participants will receive Placebo orally once daily in each 28 day treatment cycles.
All participants will receive and remain on a stable regimen of ADT (gonadotropin releasing hormone analog \[GnRHa\] or surgical castration). The choice of the GnRHa (agonist or antagonist) will be at discretion of the Investigator. Dosing (dose and frequency of administration) will be consistent with the prescribing information.
Radiographic Progression-free Survival (rPFS)
rPFS as assessed by the investigator was defined as the duration from the date of randomization to the date of first documentation of radiographic progressive disease or death due to any cause, whichever occurred first. Radiographic progressive disease was defined as progression of soft tissue lesions measured by computed tomography (CT) or magnetic resonance imaging (MRI) as defined by modified Response evaluation criteria in solid tumors (RECIST) 1.1.
Time frame: Up to 35 months
Overall Survival (OS)
OS was defined as the time from date of randomization to date of death from any cause.
Time frame: Up to 57 months
Time to Initiation of Cytotoxic Chemotherapy
Time to initiation of cytotoxic chemotherapy was defined as the time from date of randomization to the date of initiation of cytotoxic chemotherapy for prostate cancer.
Time frame: Up to 57 months
Time to Pain Progression
Time to pain progression was defined as the time from the date of randomization to the date of the first observation of pain progression. Pain progression was defined as an average increase by 2 points from baseline to greater than (\>) 4 on the Brief Pain Inventory - Short Form (BPI-SF) worst pain intensity (item 3) with no decrease in opioids confirmed greater than equal to (\>=) 3 weeks apart or initiation of chronic opioids, whichever occurred first. BPI-SF is a self-administered questionnaire developed to assess severity of pain and impact of pain on daily functions. Item 3 (worst pain intensity) asks participants to rate worst pain in prior 7-days on a 0-10 numeric rating scale, where "0" indicates "No pain" and "10" indicates "Pain as bad as you can imagine." A lower score is better.
Time frame: Up to 57 months
Time to Chronic Opioid Use
Time to chronic opioid use was defined as the time from date of randomization to the first date of confirmed chronic opioid use. For participants entering the study without receiving opioids, chronic opioid use was defined as administration of opioid analgesics lasting for greater than or equal to (\>=) 3 weeks for oral or \>=7 days for non-oral formulations. For participants entering the study already receiving opioids, chronic opioid use was defined as a \>=30 percent (%) increase in total daily dose of the opioid analgesics lasting for \>= 3 weeks for oral or \>= 7 days for non-oral formulation.
Time frame: Up to 57 months
Time to Skeletal-related Event (SRE)
Time to SRE was defined as the time from the date of randomization to the date of the first observation of an SRE. A SRE was defined as the occurrence of either a pathological fracture, or spinal cord compression, or radiation to bone, or surgery to bone.
Time frame: Up to 57 months
| Milestone | Placebo + Androgen Deprivation Therapy (ADT) | Apalutamide + ADT |
|---|---|---|
| Started | 527 | 525 |
| Completed | 527 | 524 |
| Not completed | 0 | 1 |
| Withdrew: Withdrawal by subject | 0 | 1 |
| Milestone | Placebo + Androgen Deprivation Therapy (ADT) | Apalutamide + ADT |
|---|---|---|
| Started | 527 | 524 |
| Completed | 208 | 0 |
| Not completed | 319 | 524 |
| Withdrew: Adverse event | 19 | 62 |
| Withdrew: Death | 13 | 11 |
| Withdrew: Physician decision | 4 | 6 |
| Withdrew: Protocol violation | 1 | 2 |
| Withdrew: Withdrawal by subject | 37 | 36 |
| Withdrew: Other: progressive disease | 245 | 138 |
| Withdrew: Other | 0 | 2 |
| Withdrew: Ongoing | 0 | 267 |
rPFS as assessed by the investigator was defined as the duration from the date of randomization to the date of first documentation of radiographic progressive disease or death due to any cause, whichever occurred first. Radiographic progressive disease was defined as progression of soft tissue lesions measured by computed tomography (CT) or magnetic resonance imaging (MRI) as defined by modified Response evaluation criteria in solid tumors (RECIST) 1.1.
| months | Placebo + Androgen Deprivation Therapy (ADT) | Apalutamide + ADT |
|---|---|---|
| Radiographic Progression-free Survival (rPFS) | 22.08 (18.46 to 32.92) | NA (NA to NA) |
OS was defined as the time from date of randomization to date of death from any cause.
| months | Placebo + Androgen Deprivation Therapy (ADT) | Apalutamide + ADT |
|---|---|---|
| Overall Survival (OS) | 52.17 (41.86 to NA) | NA (NA to NA) |
Time to initiation of cytotoxic chemotherapy was defined as the time from date of randomization to the date of initiation of cytotoxic chemotherapy for prostate cancer.
| months | Placebo + Androgen Deprivation Therapy (ADT) | Apalutamide + ADT |
|---|---|---|
| Time to Initiation of Cytotoxic Chemotherapy | NA (NA to NA) | NA (NA to NA) |
Time to pain progression was defined as the time from the date of randomization to the date of the first observation of pain progression. Pain progression was defined as an average increase by 2 points from baseline to greater than (\>) 4 on the Brief Pain Inventory - Short Form (BPI-SF) worst pain intensity (item 3) with no decrease in opioids confirmed greater than equal to (\>=) 3 weeks apart or initiation of chronic opioids, whichever occurred first. BPI-SF is a self-administered questionnaire developed to assess severity of pain and impact of pain on daily functions. Item 3 (worst pain intensity) asks participants to rate worst pain in prior 7-days on a 0-10 numeric rating scale, where "0" indicates "No pain" and "10" indicates "Pain as bad as you can imagine." A lower score is better.
| months | Placebo + Androgen Deprivation Therapy (ADT) | Apalutamide + ADT |
|---|---|---|
| Time to Pain Progression | NA (51.32 to NA) | NA (NA to NA) |
Time to chronic opioid use was defined as the time from date of randomization to the first date of confirmed chronic opioid use. For participants entering the study without receiving opioids, chronic opioid use was defined as administration of opioid analgesics lasting for greater than or equal to (\>=) 3 weeks for oral or \>=7 days for non-oral formulations. For participants entering the study already receiving opioids, chronic opioid use was defined as a \>=30 percent (%) increase in total daily dose of the opioid analgesics lasting for \>= 3 weeks for oral or \>= 7 days for non-oral formulation.
| months | Placebo + Androgen Deprivation Therapy (ADT) | Apalutamide + ADT |
|---|---|---|
| Time to Chronic Opioid Use | NA (51.32 to NA) | NA (NA to NA) |
Time to SRE was defined as the time from the date of randomization to the date of the first observation of an SRE. A SRE was defined as the occurrence of either a pathological fracture, or spinal cord compression, or radiation to bone, or surgery to bone.
| months | Placebo + Androgen Deprivation Therapy (ADT) | Apalutamide + ADT |
|---|---|---|
| Time to Skeletal-related Event (SRE) | NA (51.78 to NA) | NA (NA to NA) |
Collected over Up to 57 months. Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo + Androgen Deprivation Therapy (ADT) | 35/527 (6.6%) | 115/527 (21.8%) | 485/527 (92%) |
| Placebo + ADT to Apalutamide + ADT | 10/208 (4.8%) | 29/208 (13.9%) | 153/208 (73.6%) |
| Apalutamide + ADT | 31/524 (5.9%) | 153/524 (29.2%) | 494/524 (94.3%) |
| Event | Placebo + Androgen Deprivation Therapy (ADT) | Placebo + ADT to Apalutamide + ADT | Apalutamide + ADT |
|---|---|---|---|
| PneumoniaInfections and infestations | 3/527 | 3/208 | 10/524 |
| HaematuriaRenal and urinary disorders | 3/527 | 1/208 | 10/524 |
| Urinary RetentionRenal and urinary disorders | 9/527 | 0/208 | 4/524 |
| Myocardial InfarctionCardiac disorders | 0/527 | 0/208 | 8/524 |
| Cerebrovascular AccidentNervous system disorders | 1/527 | 3/208 | 4/524 |
| AnaemiaBlood and lymphatic system disorders | 6/527 | 0/208 | 1/524 |
| Back PainMusculoskeletal and connective tissue disorders | 6/527 | 0/208 | 4/524 |
| Spinal Cord CompressionNervous system disorders | 6/527 | 0/208 | 2/524 |
| Non-Cardiac Chest PainGeneral disorders | 1/527 | 2/208 | 0/524 |
| SepsisInfections and infestations | 2/527 | 2/208 | 0/524 |
| Event | Placebo + Androgen Deprivation Therapy (ADT) | Placebo + ADT to Apalutamide + ADT | Apalutamide + ADT |
|---|---|---|---|
| Hot FlushVascular disorders | 87/527 | 3/208 | 121/524 |
| Back PainMusculoskeletal and connective tissue disorders | 108/527 | 11/208 | 106/524 |
| FatigueGeneral disorders | 87/527 | 15/208 | 107/524 |
| RashSkin and subcutaneous tissue disorders | 23/527 | 26/208 | 106/524 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 82/527 | 15/208 | 101/524 |
| HypertensionVascular disorders | 84/527 | 13/208 | 100/524 |
| Weight IncreasedInvestigations | 92/527 | 7/208 | 55/524 |
| AnaemiaBlood and lymphatic system disorders | 71/527 | 13/208 | 68/524 |
| Pain in ExtremityMusculoskeletal and connective tissue disorders | 67/527 | 8/208 | 69/524 |
| ConstipationGastrointestinal disorders | 57/527 | 6/208 | 58/524 |
| Age, Continuous(years) | Placebo + Androgen Deprivation Therapy (ADT) | Apalutamide + ADT | Total |
|---|---|---|---|
| Mean | 67.9 ± 8.42 | 68.9 ± 8.11 | 68.4 ± 8.28 |
| Sex: Female, Male(Participants) | Placebo + Androgen Deprivation Therapy (ADT) | Apalutamide + ADT | Total |
|---|---|---|---|
| Female | 0 | 0 | 0 |
| Male | 527 | 525 | 1052 |
| Race (NIH/OMB)(Participants) | Placebo + Androgen Deprivation Therapy (ADT) | Apalutamide + ADT | Total |
|---|---|---|---|
| American Indian or Alaska Native | 11 | 6 | 17 |
| Asian | 112 | 119 | 231 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 9 | 10 | 19 |
| White | 365 | 354 | 719 |
| More than one race | 0 | 1 | 1 |
| Unknown or Not Reported | 30 | 35 | 65 |
| Region of Enrollment(participants) | Placebo + Androgen Deprivation Therapy (ADT) | Apalutamide + ADT | Total |
|---|---|---|---|
| ARGENTINA | 20 | 17 | 37 |
| AUSTRALIA | 5 | 6 | 11 |
| BRAZIL | 38 | 54 | 92 |
| CANADA | 16 | 14 | 30 |
| CHINA | 46 | 48 | 94 |
| CZECH REPUBLIC | 12 | 19 | 31 |
| FRANCE | 8 | 8 | 16 |
| GERMANY | 10 | 7 | 17 |
| HUNGARY | 11 | 13 | 24 |
| ISRAEL | 8 | 6 | 14 |
| ITALY | 18 | 16 | 34 |
| JAPAN | 23 | 28 | 51 |
| MEXICO | 25 | 23 | 48 |
| POLAND | 12 | 7 | 19 |
| ROMANIA | 7 | 4 | 11 |
| RUSSIAN FEDERATION | 66 | 65 | 131 |
| SOUTH KOREA | 41 | 35 | 76 |
| SPAIN | 12 | 8 | 20 |
| SWEDEN | 8 | 8 | 16 |
| TURKEY | 22 | 28 | 50 |
| UKRAINE | 60 | 42 | 102 |
| UNITED KINGDOM | 16 | 20 | 36 |
| UNITED STATES | 43 | 49 | 92 |
| Race (NIH/OMB)(participants) | Placebo + Androgen Deprivation Therapy (ADT) | Apalutamide + ADT | Total |
|---|---|---|---|
| American Indian or Alaska Native | 11 | 6 | 17 |
| Asian | 112 | 119 | 231 |
| Black or African American | 9 | 10 | 19 |
| More than one race | 0 | 1 | 1 |
| Not Reported | 8 | 11 | 19 |
| Other | 22 | 24 | 46 |
| White | 365 | 354 | 719 |
Showing the first 100 of 220 sites across 22 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Nov 2015 to primary completion in Sep 2020, 57 months.
Results were first posted in Jan 2022, 1 year 4 months after primary completion.
Of 126 industry-sponsored phase 3 interventional studies under Prostatic Neoplasms, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 53. This study's 57 months is above that.
Counting every sponsor, half of 265 studies reached it within 57 months; a quarter within 31 and three quarters within 100.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Apalutamide
Aragon Pharmaceuticals, Inc. →